Q & A

Read the latest PLC CEO interviews. CEO’s from UK listed PLC’s, Analysts and Fund Managers answering questions about their business.

Goodbody Health’s PhytoVista in a good place in terms of meeting current and future regulatory requirements (AQSE:GDBY)

Goodbody Health Group Inc (AQSE:GDBY) subsidiary PhytoVista Laboratories Chief Scientific Officer Nick Clarkson caught up with DirectorsTalk for an exclusive interview to discuss the extension of the scope of ISO..

February 14, 2022

itim Group CEO “very optimistic for the prospects for the business” (LON:ITIM)

itim Group plc (LON:ITIM) Founder and Chief Executive Officer Ali Athar caught up with DirectorsTalk for an exclusive interview to discuss what the company does, its typical customers, its impressive..

February 14, 2022

Cadence Minerals first phase of investment in Amapá completes (LON:KDNC)

Cadence Minerals plc (LON:KDNC) Chief Executive Officer Kiran Morzaria caught up with DirectorsTalk for an exclusive interview to discuss the completion of phase one of their investment in the Amapá..

February 10, 2022

Strix Group share price “could bounce back as we get strong earnings this year “says Zeus Capital (LON:KETL)

Strix Group plc (LON:KETL) is the topic of conversation when Zeus Capital’s Research Director Andy Hanson caught up with DirectorsTalk for an exclusive interview. Q1: Strix Group have released a..

February 10, 2022

Cizzle Biotechnology commercial & royalty agreement represents a very significant deal for the company (LON:CIZ)

Cizzle Biotechnology Holdings plc (LON:CIZ) Executive Chairman Allan Syms caught up with DirectorsTalk for an exclusive interview to discuss the commercial and royalty agreement to develop and market their early..

February 9, 2022

Open Orphan open for business to deal with big pharma and biotechs (LON:ORPH)

Open Orphan plc (LON:ORPH) Executive Chairman Cathal Friel caught up with DirectorsTalk for an exclusive interview to discuss the results from the COVID-19 characterisation study, the next phase of the..

February 9, 2022

Tirupati Graphite growth and momentum to continue (LON:TGR)

Tirupati Graphite plc (LON:TGR) Executive Chairman and Managing Director Shishir Poddar caught up with DirectorsTalk for an exclusive interview to discuss hitting production targets and what it’ll mean for the..

February 9, 2022

Quadrise Fuels International test results will support and hopefully accelerate the plans on the larger scale trials (LON:QFI)

Quadrise Fuels International plc (LON:QFI) Chief Executive Officer Jason Miles caught up with DirectorsTalk for an exclusive interview to discuss new Chairman Andy Morrison, the significant for bioMSAR as a..

February 9, 2022

Fintel doing well, both financially and operationally says Zeus Capital

Fintel plc (LON:FNTL) is the topic of conversation when Zeus Capital’s Research Analyst Robin Savage caught up with DirectorsTalk for an exclusive interview. Q1: Robin, what were the key points..

February 8, 2022

Staffline Group “good organic growth rate and platform is in a good shape” says Zeus Capital (LON:STAF)

Staffline plc (LON:STAF) is the topic of conversation when Zeus Capital’s Head of Research Mike Allen caught up with DirectorsTalk for an exclusive interview. Q1: Mike, first off, can you..

February 8, 2022

LSL Property Services attractive dividend, no net debt and strategically positioned to continue growing (LON:LSL)

LSL Property Services plc (LON:LSL) is the topic of conversation when Zeus Capital’s Research Analyst Robin Savage caught up with DirectorsTalk for an exclusive interview. Q1: Following on from LSL..

February 1, 2022

Safestyle UK operating environment remains sound and could outperform its peers (LON:SFE)

Safestyle UK plc (LON:SFE) is the topic of conversation when Zeus Capital’s Research Director Andy Hanson caught up with DirectorsTalk for an exclusive interview. Q1: We’ve just seen a full..

February 1, 2022

Lookers share price remains very cheap and strategy is very exciting (LON:LOOK)

Lookers plc (LON:LOOK) is the topic of conversation when Zeus Capital’s Head of Research Mike Allen caught up with DirectorsTalk for an exclusive interview. Q1: Mike, you’ve published a note..

February 1, 2022

Goodbody Health: Independent pharmacy offers solution to NHS challenges (AQSE:GDBY)

Goodbody Health Inc. (AQSE:GDBY) Scientific Advisory Committee Member and Chair of the Pharmacy Focus Group Ian Strachan caught up with DirectorsTalk for an exclusive interview to discuss his background in..

January 27, 2022

Epwin Group “exceptionally strong performance on the top line” says Zeus Capital (LON:EPWN)

Epwin Group plc (LON:EPWN) is the topic of conversation when Zeus Capital’s Research Director Andy Hanson caught up with DirectorsTalk for an exclusive interview. Q1: Andy, it looks like FY21..

January 26, 2022

Ilika “well-funded to get through and into commercialisation of Stereax and to fund Goliath” says Baden Hill (LON:IKA)

Ilika plc (LON:IKA) is the topic of conversation when Baden Hill Partners’ Clean Tech Equities Specialist Dr Tom McColm caught up with DirectorsTalk for an exclusive interview. Q1: Ilika announced..

January 26, 2022

Anexo Group’s housing disrepair business to be a significant contributor to revenues in 2022 and beyond (LON:ANX)

Anexo Group plc (LON:ANX) Head of Investor Relations Nick Dashwood Brown caught up with DirectorsTalk for an exclusive interview to discuss record fleet numbers, motorcycle courier business, housing disrepair business..

January 26, 2022

City of London Investment Group “a reliable business, well controlled and delivering an attractive dividend” says Zeus Capital (LON:CLIG)

City of London Investment Group plc (LON:CLIG) is the topic of conversation when Zeus Capital’s Research Analyst Robin Savage caught up with DirectorsTalk for an exclusive interview. Q1: City of..

January 25, 2022

Helium One exciting exploration campaign as they move into 2022 (LON:HE1)

Helium One Global plc (LON:HE1) Chief Executive Officer David Minchin caught up with DirectorsTalk for an exclusive interview to discuss the completion of a multispectral satellite spectroscopy identifying multiple helium..

January 21, 2022

Poolbeg Pharma very excited about the potential of University of Warwick deal (LON:POLB)

Poolbeg Pharma plc (LON:POLB) Chief Executive Officer Jeremy Skillington caught up with DirectorsTalk for an exclusive interview to discuss the in-licenced novel, first-in-class RNA-based immunotherapy for respiratory virus infections developed..